Slingshot members are tracking this event:

Phase 3 GAUSS-3 Trial Of Repatha (Evolocumab) In Statin-Intolerant Patients With High Cholesterol Meets Co-Primary Endpoints of LDL Cholesterol Reduction

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details The study met its co-primary endpoints: mean percent reductions from baseline in low-density lipoprotein cholesterol (LDL-C) at weeks 22 and 24, and the percent reduction from baseline in LDL-C at week 24. The mean percent reductions in LDL-C, or "bad" cholesterol, compared to ezetimibe, were consistent with results observed in the 12-week Phase 2 GAUSS-1 and Phase 3 GAUSS-2 trials.

In the GAUSS-3 trial there were no new safety findings. The most common adverse events that occurred in greater than 5 percent of patients in the Repatha group were myalgia, nasopharyngitis, muscle spasms, arthralgia, pain in extremity, fatigue, headache and back pain.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 04, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Trial, Gauss-3, Evolocumab, Statin-intolerant Patients, High Cholesterol, Ldl Cholesterol Reduction, Primary Endpoints, Repatha, Low-density Lipoprotein Cholesterol, Statins